Generics

Generic Valcyte is a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor indicated for several conditions in pediatric and adult patients.

The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.

The study reveals provider perceptions of commercially available biosimilars and anticipated launches, which have the potential to increase equitable access to critical treatments.

The new report from Matrix Global Advisors illustrates the complexities of the burgeoning adalimumab biosimilar market, the Biosimilars Council said.

Lurasidone, an oral atypical antipsychotic, is a first-line treatment option for the management of schizophrenia in adults and adolescents.

Christine Baeder, senior vice president and chief operating officer for U.S. generics, Teva Pharmaceuticals USA is the 2023 AAM chair of the board.

Generic Latuda is used to treat a depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients as monotherapy.

An aging population combined with increasing numbers of people diagnosed with chronic diseases are among the top factors set to influence innovation in the generics drug market in 2023.